Collegium Pharmaceutical Inc. to Engage with Investors at Key Conferences
May 19, 2025 — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a health care company specializing in pharmaceutical products for central nervous system, respiratory, and skin-related disorders, has announced its participation in two significant investor conferences. The company, headquartered in Stoughton, Massachusetts, is set to present at the Mizuho Neuro & Ophthalmology Summit 2025 and the Jefferies Global Healthcare Conference.
Conference Participation Details
Mizuho Neuro & Ophthalmology Summit 2025: Collegium’s management will participate in a panel presentation on Wednesday, May 21, 2025, at 11:25 a.m. ET. This event will provide an opportunity for the company to discuss its strategic initiatives and product developments in the neurology and ophthalmology sectors.
Jefferies Global Healthcare Conference: A presentation by Collegium is scheduled for Thursday, June 5, 2025, at 1:25 p.m. ET. This presentation will be webcast live and can be accessed from the Investors section of Collegium’s website at https://ir.collegiumpharma.com . A replay of the webcast will be available on the company’s website for 90 days following the presentation.
Company Overview
Collegium Pharmaceutical, Inc. is committed to improving the lives of individuals with serious medical conditions through its diversified biopharmaceutical portfolio. The company is known for its responsible pain management medications and has recently expanded its presence in neuropsychiatry with the acquisition of Jornay PM®, a treatment for ADHD. Collegium’s strategy focuses on growing its commercial portfolio, with Jornay PM as a key growth driver, while deploying capital in a disciplined manner.
Financial Snapshot
As of May 15, 2025, Collegium’s stock closed at $30.23. The company’s 52-week high was $42.2873 on October 6, 2024, and its 52-week low was $23.23 on April 9, 2025. With a market capitalization of approximately $943 million, Collegium’s price-to-earnings ratio stands at 24.25. The company is listed on the Nasdaq stock exchange and was initially public in May 2015.
Collegium’s upcoming participation in these investor conferences is expected to provide valuable insights into its strategic direction and growth prospects, offering investors a closer look at the company’s future plans and performance.